GLP1R and type 2 diabetes mellitus: In addition, in patients with T2DM and moderate to severe reduced estimated GFR, GLP-1 receptor agonist dulaglutide reduced hemoglobin A1c similarly to basal insulin glargine, but with the added benefit of weight loss, lower rate of hypoglycemia, and a reduced decline in renal function [89].